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ABSTRACT A series of nitraquazone analogs with a pyrimidindione core was synthesized and tested
for inhibitory activity on PDE4, selectivity versus PDE3 and PDE5 and for affinity towards the rolipram
high-affinity binding site (HARBS). The 5-anilino derivatives 13–18 showed the best profile combining
appreciable PDE4 inhibitory activity (IC505 5–14 mM) with a good selectivity toward PDE3 and PDE5. The
same compounds demonstrate low affinity for the HARBS site with IC50 values of 12–69 mM (IC50 for
Rolipram5 3.6 nM). Drug Dev Res 72:274–288, 2011. r 2010 Wiley-Liss, Inc.
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INTRODUCTION
Phosphodiesterases are a superfamily of enzymes
responsible for the hydrolysis of cAMP and cGMP
to the corresponding nucleosides, AMP and GMP.
Eleven different families have been described
(PDE1–PDE11), but the role, the characteristics, as
well as the specific inhibitors of the newer discovered
types PDE8-PDE11 have not yet been widely defined
[Lugnier, 2006]. The PDE4 family, which selectively
hydrolyzes cAMP, is mainly present in inflammatory
cells, brain, and cardiovascular tissue [Tenor and
Schudt, 1996; Houslay et al., 1998; Stoclet et al.,
1995] and constitutes four subtypes, PDE4A–D
[Houslay, 2001]. The involvement of PDE4 in patho-
logical processes in these tissues indicates that
compounds able to modulate PDE4 activity could have
use in a variety of diseases [Houslay et al., 2005].
PDE4 inhibitors have been widely studied for the
treatment of asthma and chronic obstructive pulmon-
ary disease (COPD) [Lipworth, 2005; Dal Piaz and
Giovannoni, 2000] as they suppress many of the
neutrophil responses responsible for pathological
inflammatory process, including the production of
IL-8, superoxide anions, degranulation, chemotaxis,
and adhesion [Houslay et al., 2005]. PDE4 inhibitors
could ameliorate the mucus hypersecretion that
characterizes asthma and COPD by reducing the
transcriptional activity of MUC5AC, a regulator gene
in mucin secretion [Mat et al., 2005]. Moreover, PDE4
inhibitors reduce superoxide anion production from
eosinophils as well as the adhesion and infiltration of
the latter, suggesting a potential role in allergic rhinitis,
asthma, and atopic dermatitis [Spina, 2004]. PDE4
inhibitors can also reduce tumor necrosis factor-a
(TNFa) production suggesting a role in rheumatoid
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arthritis, psoriasis, and Crohn’s disease [Seldon et al.,
1995; Jimenez et al., 2001]. PDE4 inhibitors can also
induce cell cycle arrest and apoptosis in limphoblastic
leukaemia cells [Ogawa et al., 2002] and block
angiogenic response of endothelial cells [Favot et al.,
2004], suggesting possible applications in oncology. The
antidepressant effect of PDE inhibitors has been
considered. Despite initial studies where PDE4
inhibitors had a potent antidepressant action
[O’Donnel, 1993], no further progress has occurred
because of an incomplete understanding of the
functional importance of PDE4 subtypes and of low-
and high-affinity rolipram binding site (HARBS) for
pathology [O’Donnel and Zhang, 2004]. Finally, PDE4
inhibitors have shown efficacy in the MPTP mouse
model [Zhang et al., 2004], suggesting potential in
Parkinson’s disease. Rolipram 1 (Fig. 1), the prototypic
PDE4 inhibitor, was extensively investigated as an
antidepressant more than two decades ago but side
effects including nausea, vomiting, and headache, related
to binding to HARBS, limited its clinical potential
[Schneider et al., 1986; Sounes and Rao, 1997]. Many
PDE4 inhibitors of different chemical classes have also
been in clinical trials for the treatment of asthma, but
they were discontinued because of side effects.
The disconnect between HARBS affinity and
PDE4 inhibition found in more recent compounds
allowed the selection of a number of molecules that are
currently in clinical trials. Roflumilast 2 [Hatzeman and
Schudt, 2001; Karish and Gagnon, 2006] is the most
advanced PDE4 inhibitor, having been approved in the
EU for severe COPD associated with chronic bron-
chitis area in 2010. Cilomilast 3 [Christensen et al.,
1998; Barnette et al., 1998] and tofimilast 4 [Duplantier
et al., 2007; Bayes et al., 2007] are selective PDE4
inhibitors. The former is being studied for the
treatment of emphysema and bronchitis while the
latter was discontinued because of unacceptable side
effects. Other PDE4 inhibitor molecules in clinical
trials include apremilast 5 [Khobzaoui et al., 2005]
(CC10004), which is being evaluated in psoriatic
arthritis and refractory psoriasis [http://clinicaltrial.
gov/.], and tetomilast 6 [Bloomfield et al., 1997;
O’Mahony, 2005] (OPC-6535), which has been recently
studied in patients with ulcerative colitis, Crohn’s
disease, and COPD (Phase II) [http://clinicaltrial.gov/.].
CC-1088 7 [Muller et al., 1998] is structurally related
to 5.
In the last decade, we reported [Dal Piaz et al.,
1997, 1998; Giovannoni et al., 2007] on heterocyclic-
fused 3-(2H)-pyridazinones with appreciable activity as
PDE-4 inhibitors, good selectivity toward PDE3
isoenzyme, and, in some cases, low affinity for
[3H]rolipram binding site. The more interesting
compounds were further investigated [Martin et al.,
2002; Pieretti et al., 2006].
In the present work, we have designed and
synthesized a new series of pyrimidine-2,4-diones as
simplified analogues of nitraquazone 8, a prototypic
PDE4 inhibitor [Glaser and Traber, 1984; Russo et al.,
1987] and report on their PDE4 inhibitory activity,
selectivity versus PDE3/PDE5, and affinity for
HARBS.
MATERIALS AND METHODS
Chemistry
All melting points were determined on a Buchi
apparatus and are uncorrected. 1H-NMR spectra were
recorded with Avance 400 instruments (Bruker Biospin,
version 002 with SGU). Chemical shifts are reported in
ppm, using the solvent as internal standard. Extracts
were dried over Na2SO4 and the solvents were
removed under reduced pressure. E. Merck (West
Point, PA) F-254 commercial plates were used for
analytical TLC to follow the course of the reaction.
Silica gel 60 (Merck 70-230 mesh) was used for column
chromatography.
[3H]-cAMP, [3H]-cGMP, and [3H]Rolipram
were from Perkin-Elmer Life and Analytical Science
(Waltham, MA); all other chemicals were purchased
from Sigma-Aldrich (St. Louis, MO) (Fig. 1).
The synthesis of the novel pyrimidine-2,4-diones
substituted at position 1, 3, and 5 is depicted in Figures
2–4. In Figures 2 and 3, the procedure to afford the
5-substituted aniline derivatives 13a–d and 18a–c is
reported. In both instances, the starting material is
represented by the previously described pyrimidine-
2,4-diones 9a,b [Winckelmann and Larsen, 1986;
Robin et al., 2006] and 14 [Winckelmann and Larsen,
1986]. In Figure 2, the first step is a bromination at
position 5 performed with bromine in acetic acid;
treatment of the intermediates 10a,b (10a) [Moltke-
Leth and Joergensen, 1993] with concentrated ammo-
nia afforded the 5-amino derivatives 11a,b, which were
alkylated in standard condition to give 12a,b. The last
step to obtain the final compounds 13a–d was
performed through a cross-coupling reaction with the
appropriate aryl boronic acids using copper acetate as
catalyst and a weak base (triethylamine) in CH2Cl2
[Quach and Batey, 2003; Chiang and Olsson, 2004].
Similarly, compounds 18a–c were obtained starting
from the 5-amino derivatives 17a,b, following the
above described cross-coupling reaction. In this synthetic
route, compound 15, obtained by alkylation from the
precursor 14, was nitrated with a mixture of potassium
nitrate and sulfuric acid to afford compound 16.
Treatment of compound 16 with stannous chloride in
275NITRAQUAZONE PDE4 INHIBITORS
Drug Dev. Res.
hydrochloric acid using a 1:1 molar ratio selectively
reduced the nitro group at position 5 to give the
corresponding 5-amino derivative 17a. Reduction of
both nitro groups at position 5 and in para position of
the phenyl ring was performed using a 1:5 molar ratio
of substrate 16 and stannous chloride to yield 17b. In
Figure 4, the common precursors are again repre-
sented by 5-bromo pyrimidine-2,4-diones 10a–c (10c)
[Gutschow et al., 2001], which, in the first route, were
alkylated under standard conditions affording 19a–d,
which, in turn, were subjected to a cross-coupling
reaction under classical Suzuki conditions using tetra-
kis(triphenylphosphine)palladium and the opportune
phenylboronic acid in toluene [Wang and Haseltine,
1994] to give the final 5-(substituted)aryl pyrimidine-
2,4-diones 20a–m. In the second route, the bromine at
position 5 was displaced with 4-chloro-benzylamine to
give compound 21, which, treated with ethyl bromide,
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Fig. 1. PDE4 inhibitors.
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afforded the final compound 22. Finally, several
molecules with pyridine-2-one core (24a–c) were
synthesized starting from previously described pre-
cursors 23a,b [Bormann, 1981; Hagen et al., 1990],
performing an alkylation at position 1 (Fig. 5).
5-Bromo-1-p-tolyl-1H-pyrimidine-2,4-dione (10b)
To a stirred mixture of 9b (0.74 mmol) in glacial
acetic acid (7 mL), a solution of bromine (0.74 mmol) in
the same solvent (0.5 mL) was added in a dropwise
manner (over a 2-h period). The mixture was stirred for
1 h, concentrated in vacuo to afford a residue that,
when treated with cold water (15 mL), gave rise to a
crude precipitate that was recovered by suction.
Mp5 202–2051C; crystallization solvent5EtOH;
yield5 70%. 1H-NMR (CDCl3), d: 2.45 (3H, s),
7.20–7.35 (4H, m), 7.70 (1H, s), 8.50 (1H, exch br s).
General Procedure for Compounds (11a,b)
To the appropriate 5-bromopyrimidin-2,4-dione
(10a or 10b, 0.76 mmol), 4 mL of concentrated
ammonia was added. The reaction was carried out in
a sealed tube at 1201C for 4 h. After, the mixture was
concentrated in vacuo and the residue was treated with
cold ethanol to afford a crude solid that was collected
by suction.
5-Amino-1-(4-chlorophenyl)-1H-pyrimidine-
2,4-dione (11a) Mp43001C; crystallization solvent5
EtOH; yield5 61%. 1H-NMR (DMSO), d: 4.25 (2H,
exch br s), 6.85 (1H, s), 7.45 (2H, d, J5 8.5 Hz), 7.55
(2H, d, 8.5 Hz), 11.50 (1H, exch br s).
5-Amino-1-p-tolyl-1H-pyrimidine-2,4-dione
(11b) Mp5 227–2291C; crystallization solvent5
EtOH; yield5 80%. 1H-NMR (DMSO), d: 2.35
(3H, s), 4.20 (2H, exch br s), 6.80 (1H, s), 7.30
(4H, s), 11.45 (1H, exch br s).
General Procedure for Compounds (12a,b)
A mixture of the appropriate pyrimidin-2,4-dione
(11a or 11b, 0.5 mmol), anhydrous K2CO3 (1 mmol),
and ethyl bromide (0.75 mmol) in anhydrous DMF
(2 mL) was heated under stirring for 40–120 min at
60–901C. After dilution with cold water, the crude
precipitate 12a was recovered by suction, while
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Fig. 2. Synthesis of 5-(substituted)anilino pyrimidine-2,4-diones 13a–d. Reagents and conditions: (a) Br2, AcOH 100%, rt, 3h; (b) NH4OH 33%,
sealed tube, 1201C, 5 h; (c) EtBr, DMF, K2CO3, 901C, 1h; (d) X-C6H5-B(OH)2, CH2Cl2, Ac2Cu, Et3N, rt, 24 h.
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compound 12b was extracted (3 20 mL) with ethyl
acetate (30–40 mL).
5-Amino-1-(4-chlorophenyl)-3-ethyl-1H-pyri-
midine-2,4-dione (12a) Mp5 1901C; crystallization
solvent5EtOH; yield5 63%. 1H-NMR (DMSO),
d: 1.15 (3H, t, J5 7.2 Hz), 3.90 (2H, q, J5 7.2 Hz),
4.30 (2H, exch br s), 6.90 (1H, s), 7.45 (2H, d,
J5 8.9 Hz), 7.55 (2H, d, J5 8.9 Hz).
5-Amino-1-p-tolyl-3-ethyl-1H-pyrimidine-2,4-
dione (12b) Mp5 157–1601C; crystallization solvent5
EtOH; yield5 64%. 1H-NMR (DMSO), d: 1.15 (3H, t,
J5 7.2 Hz), 2.35 (3H, s), 3.90 (2H, q, J5 7.2 Hz), 4.25
(2H, exch br s), 6.85 (1H, s), 7.30 (4H, s).
General Procedure for Compounds (13a–d)
A mixture of activated molecular sieves (0.8–1 g),
the substrates 12a or 12b (0.5 mmol), the appropriate
boronic acid (0.5 mmol) commercially available, copper
acetate (0.8 mmol), and triethylamine (1 mmol) in
CH2Cl2 (10 mL) were stirred for 6–24 h at rt 401C.
The molecular sieves together with copper salts were
filtered off and the solution was extracted first with
concentrated ammonia (2 5 mL) and then with water
(2 5 mL). The organic layer was evaporated in vacuo
and the residue recovered by suction (compounds
13c,d). For compounds 13a,b, evaporation of the solvent
afforded an oil that was purified by column chromato-
graphy using cyclohexane/ethyl acetate 1:2 as eluent.
1-(4-Chlorophenyl)-3-ethyl-5-(3-nitropheny-
lamino)-1H-pyrimidine-2,4-dione (13a) Mp5
190–1931C; purified by column chromatography
(cyclohexane/ethyl acetate 1:2); yield5 20%. 1H-
NMR (DMSO), d: 1.25 (3H, t, J5 7.1 Hz), 3.90 (2H,
q, J5 7.1 Hz), 7.20 (1H, d, J5 8.8 Hz), 7.40 (1H, dd,
J5 2.2, 8.8 Hz), 7.50 (1H, d, J5 8.8 Hz), 7.55 (5H, m),
7.80 (1H, exch br s), 7.85 (1H, s). Anal. Calcd for
C18H15ClN4O4: C, 55.89; H, 3.91; N, 14.49. Found: C,
56.00; H, 3.92; N, 14.52.
1-(4-Chlorophenyl)-5-(3-chlorophenylamino)-3-
ethyl-1H-pyrimidine-2,4-dione (13b) Mp5117–1201C;
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Fig. 3. Synthesis of 5-(substituted)anilino pyrimidine-2,4-diones 18a,b. Reagents and conditions: (a) EtBr, DMF, K2CO3, 901C, 1 h; (b) KNO3,
conc. H2SO4, rt, 8 h; (c) SnCl2, conc HCl, rt, 1 h; (d) ArB(OH)2, CH2Cl2, Ac2Cu, Et3N, rt, 24 h.
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purified by column chromatography (cyclohexane/
ethyl acetate 1:2); yield5 20%. 1H-NMR (CDCl3), d:
1.30 (3H, t, J5 7.2 Hz), 4.15 (2H, q, J5
7.2 Hz), 6.85 (1H, d, J5 9.0 Hz), 6.90 (1H, d,
J5 9.0 Hz), 7.00 (1H, s), 7.20 (2H, m), 7.30–7.50
(4H, m), 7.90 (1H, exch br s). Anal. Calcd for
C18H15Cl2N3O2: C, 57.46; H, 4.02; N, 11.17. Found:
C, 57.57; H, 4.03; N, 11.19.
3-Ethyl-5-(3-nitrophenylamino)-1-p-tolyl-1H-
pyrimidine-2,4-dione (13c) Mp5 200–2031C;
crystallization solvent5EtOH; yield5 17%.1H-NMR
(DMSO), d: 1.15 (3H, t, J5 7.2 Hz), 2.35 (3H, s), 3.90
(2H, q, J57.2 Hz), 7.20 (1H, d, J58.7 Hz), 7.35 (5H, m),
7.50 (1H, d, J58.7 Hz), 7.55 (1H, s), 7.80 (1H, s), 7.85
(1H, exch br s). Anal. Calcd for C19H18N4O4: C, 62.29; H,
4.95; N, 15.29. Found: C, 62.41; H, 4.96; N, 15.32.
3-(3-Ethyl-2,4-dioxo-1-p-tolyl-1,2,3,4-tetrahy-
dropyrimidin-5-yl-amino)benzoic acid ethyl ester
(13d) Mp5 130–1351C; crystallization solvent5
EtOH; yield5 20%.1H-NMR (CDCl3), d: 1.30 (3H, t,
19 R R1
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Fig. 4. Synthesis of 5-(substituted)phenyl pyrimidine-2,4-diones 20a–m and of compound 22. Reagents and conditions: (a) R1Br, DMF, K2CO3, 901C,
1h; (b) X-C6H5-B(OH)2, Pd(PPh3)4, 2M Na2CO3, toluene, 901C, 16h; (c) 4-chlorobenzylamine, EtOH, 901C, 9h; (d) EtBr, DMF, K2CO3, 901C, 1h.
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J5 7.2 Hz), 1.40 (3H, t, J5 7.2 Hz), 2.40 (3H, s), 4.15
(2H, q, J5 7.2 Hz), 4.40 (2H, q J5 7.2 Hz), 7.15 (1H,
d, J5 8.8 Hz), 7.30 (6H, m), 7.60 (1H, d, J5 8.8 Hz),
7.70 (1H, s), 7.85 (1H, exch br s).
Anal. Calcd for C22H23N3O4: C, 67.16; H, 5.89;
N, 10.68. Found: C, 67.29; H, 5.90; N, 10.70.
3-Ethyl-1-phenyl-1H-pyrimidine-2,4-dione (15)
Compound 15 was obtained from compound 14
following the general procedure described for 13a–d.
After dilution with cold water, the suspension was
extracted with ethyl acetate (3 20 mL) and the
solvent was evaporated in vacuo to afford 15.
Mp5 119–1211C; crystallization solvent5EtOH;
yield5 20%. 1H-NMR (CDCl3), d: 1.30 (3H, t,
J5 7.0 Hz), 4.10 (2H, q, J5 7.0 Hz), 5.90 (d, 1H,),
7.30–7.55 (6H, m).
3-Ethyl-5-nitro-1-(4-nitrophenyl)-1H-pyrimi-
dine-2,4-dione (16) A mixture of pyrimidine-2,4-
dione 15 (0.46 mmol) KNO3 (1.84 mmol) and 0.1 mL
of concentrated H2SO4 (1.84 mmol) was heated at
1001C in a sealed tube for 3 h. After cooling, cold water
was added and the precipitate filtered off. Mp5 1121C
dec.; crystallization solvent5EtOH; yield5 90%.
1H-NMR (CDCl3), d: 1.35 (3H, t, J5 7.0 Hz), 4.15
(2H, q, J5 7.0 Hz), 7.65 (2H, d, J5 8.8 Hz), 8.45 (2H,
d, J5 8.8 Hz), 8.80 (s, 1H, 6-CH).
General Procedure for Compounds (17a,b)
To a mixture of compound 16 (0.30 mmol) and
concentrated HCl (0.8 mL), a solution of SnCl2
(0.3 mmol to obtain compound 17a and 1.5 mmol to
obtain compound 17b) in 1 mL of concentrated HCl
was added. The reaction was carried out at room
temperature for 1 h and then 6N NaOH was added
until pH5 8. The crude precipitate was recovered by
suction.
5-Amino-3-ethyl-1-(4-nitrophenyl)-1H-pyrimi-
dine-2,4-dione (17a) MpZ3001C; crystallization
solvent5EtOH; yield5 75%. 1H-NMR (DMSO), d:
1.15 (3H, t, J5 7.1 Hz), 3.90 (2H, q, J5 7.1 Hz), 4.40
(2H, exch br s), 7.00 (1H, s), 7.75 (2H, d, J5 8.9 Hz),
8.35 (2H, d, J5 8.9 Hz).
5-Amino-3-ethyl-1-(4-aminophenyl)-1H-pyri-
midine-2,4-dione (17b) MpZ3001C; crystallization
solvent5EtOH; yield5 40%. 1H-NMR (DMSO), d:
1.10 (3H, t, J5 7.2 Hz), 3.87 (2H, q, J5 7.2 Hz), 4.14
(2H, exch br s), 5.27 (2H, exch br s), 6.56 (2H, d,
J5 8.3 Hz), 6.75 (1H, s), 6.95 (2H, d, J5 8.3 Hz r).
General Procedure for Compounds (18a–c)
Compounds 18a–c were obtained starting from
17a,b following the general procedure described for
13a–d. Evaporation of the solvent afforded 18a as a
crude precipitate and 18b,c as oil. The latter were
purified by column chromatography using cycloexane/
ethyl acetate 2:1 as eluent.
5-(3-Chlorophenylamino)-3-ethyl-1-(4-nitrophe-
nyl)- 1H-pyrimidine-2,4-dione (18a) Mp5166–1681C;
crystallization solvent5EtOH; yield55%. 1H-NMR
(CDCl3), d: 1.40 (3H, t, J57.2 Hz), 4.15 (2H, q,
J57.2 Hz), 6.90 (1H, d, J58.8 Hz), 6.95 (1H, d,
J58.8 Hz), 6.95 (3H, m), 7.25 (2H, m), 7.65 (2H, d, J5
9.0 Hz), 7.90 (1H, exch br s), 8.40 (2H, d, J59.0 Hz).
Anal. Calcd for C18H15ClN4O4: C, 55.89; H, 3.91; N,
14.49. Found: C, 56.00; H, 3.92; N, 14.52.
3-(3-Ethyl-2,4-dioxo-1-(4-nitrophenyl)-1,2,3,4-
tetrahydropyrimidin-5-yl-amino)benzoic acid ethyl
ester (18b) Mp5 129–1311C; purified by column
chromatography (cyclohexane/ethyl acetate 2:1);
yield5 30%. 1-NMR (DMSO), d: 1.30 (3H, t, J5
7.2 Hz), 1.40 (3H, t, J57.2 Hz), 4.20 (2H, q, J5 7.2 Hz),
4.40 (2H, q, J57.2 Hz), 7.10 (1H, m), 7.25 (2H, m), 7.50
(1H, m), 7.80 (3H, m), 7.90 (1H, exch br s), 8.35 (2H, d,
J58.9 Hz). Anal. Calcd for C21H20N4O6: C, 59.43; H,
4.75; N, 13.20. Found: C, 59.31; H, 4.74; N, 13.17.
3-(1-(4-aminophenyl)-3-ethyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl-amino)benzoic acid ethyl
ester (18c) Mp5105–1081C; purified by column
chromatography (cyclohexane/ ethyl acetate 2:1);
yield520%.1H-NMR (DMSO), d: 1.10 (3H, t,
J57.1 Hz), 1.27 (3H, t, J57.2 Hz), 3.89 (2H, q,
23a,b
HN
NC
O
CH3
N
NC
O
CH3
R
24a-c
a
X X
23 X 
a H
b 3,4-OCH3
24 R X 
a CH2CH3 3,4 OCH3
b cyclopropylmethyl H 
c cyclopropylmethyl 3,4 OCH3
Fig. 5. Synthesis of 1-alkylpyrimidones 24a–c. Reagents and conditions: (a) RBr, DMF (or CH3CN), K2CO3, 901C, 1h.
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J57.1 Hz), 4.24 (2H, q, J57.2 Hz), 5.40 (2H, exch br s),
6.60 (2H, d, J58.3 Hz), 7.05 (2H, d, J58.3 Hz), 7.35
(5H m), 7.85 (exch br s, 1H, NH), 8.40 (2H, d,
J58.9 Hz). Anal. Calcd for C21H22N4O4: C, 63.95; H,
5.62; N, 14.20. Found: C, 63.82; H, 5.61; N, 14.17.
General Procedure for Compounds (19a–d)
Compounds 18a–d were obtained starting from
10a–c following the general procedure described for
12a,b.
5-Bromo-1-(4-chlorophenyl)-3-ethyl-1H-pyri-
midine-2,4-dione (19a) Mp5 195–1971C; crystalliza-
tion solvent5EtOH; yield5 90%. 1H-NMR (CDCl3),
d: 1.30 (3H, t, J5 7.1 Hz), 4.10 (2H, q, J5 7.1 Hz),
7.30 (2H, d, J5 8.8 Hz), 7.50 (2H, d, J5 8.8 Hz), 7.65
(1H, s).
5-Bromo-3-ethyl-1-p-tolyl-1H-pyrimidine-2,4-
dione (19b) Mp5 176–1771C; crystallization solvent5
EtOH; yield5 81%. 1H-NMR (CDCl3), d: 1.30 (3H, t,
J5 7.3 Hz), 2.40 (3H, s), 4.15 (2H, q, J5 7.3 Hz), 7.20
(d, 2H, J5 8.8 Hz), 7.30 (d, 2H, J5 8.8 Hz), 7.65 (1H, s).
5-Bromo-3-ethyl-1-phenyl-1H-pyrimidine-2,4-
dione (19c) Mp5 184–1851C; crystallization solvent5
EtOH; yield5 100%.1H-NMR (CDCl3), d, ppm: 1.30
(3H, t, J5 7.2 Hz), 4.15 (2H, q, J5 7.2 Hz), 7.40 (d, 2H,
J5 8.8 Hz), 7.45-7.55 (3H, m), 7.70 (1H, s).
5-Bromo-3-cyclopropylmethyl-1-phenyl-1H-
pyrimidine-2,4-dione (19d) Mp5 150–1521C; crys-
tallization solvent5EtOH; yield5 96%. 1H-NMR
(CDCl3), d: 0.45 (4H, m), 1.30 (1H, m), 3.95 (2H, d,
J5 6.8 Hz), 7.35 (2H, d, J5 8.0 Hz), 7.40–7.55 (3H, m),
7.70 (1H, s).
General Procedure for Compounds (20a–m)
A mixture of the appropriate 5-bromo derivative
19 (0.3–0.6 mmol), tetrakis(triphenyl phosphine)
palladium(0) (0.017–0.025 mmol), toluene (2–3 mL),
the commercially available phenylboronic acid
(0.6–1.2 mmol) dissolved in 1–2 mL of EtOH and 2M
Na2CO3 (2–3 mL), was heated at 60–901C for 3–18 h.
After cooling, the mixture was concentrated in vacuo,
diluted with water (10 mL), and extracted with CH2Cl2
(3 10 mL). Evaporation of the solvent afforded an oil
that was purified by column chromatography. Com-
pound 20j was purified by crystallization from EtOH.
1-(4-Chlorophenyl)-3-ethyl-5-phenyl-1H-pyr-
imidine-2,4-dione (20a) Mp5 48–511C; purified by
column chromatography (toluene/ethyl acetate 8:2);
yield5 19%. 1H-NMR (CDCl3), d: 1.30 (3H, t,
J5 7.2 Hz), 4.15 (2H, q, J5 7.2 Hz), 7.35–7.45 (6H,
m), 7.50 (2H, d, J5 8.4 Hz), 7.55 (2H, d, J5 8.4 Hz).
Anal. Calcd for C18H15ClN2O2: C, 66.16; H, 4.63; N,
8.57. Found: C, 66.25; H, 4.64; N, 8.59.
1-(4-Chlorophenyl)-3-ethyl-5-(3-nitrophenyl)-
1H-pyrimidine-2,4-dione (20b) Mp5 145–1471C;
purified by column chromatography (toluene/ethyl
acetate 8:2); yield5 21%. 1H-NMR (CDCl3), d: 1.35
(3H, t, J5 7.2 Hz), 4.15 (2H, q, J5 7.2 Hz), 7.40 (2H, d,
J5 8.4 Hz), 7.50–7.65 (4H, m), 8.00–8.20 (2H, m), 8.40
(1H, s). Anal. Calcd for C18H14ClN3O4: C, 58.15; H,
3.80; N, 11.30. Found: C, 58.03; H, 3.79; N, 11.28.
1-(4-Chlorophenyl)-5-(3-chlorophenyl)-3-ethyl-
1H-pyrimidine-2,4-dione (20c) Mp563–651C; puri-
fied by column chromatography (toluene/ethyl acetate
8:2); yield517%. 1H-NMR (CDCl3), d: 1.35 (3H, t,
J57.2 Hz), 4.15 (2H, q, J57.2 Hz), 7.35–7.55 (9H, m).
Anal. Calcd for C18H14Cl2N2O2: C, 59.85; H, 3.91; N,
7.76. Found: C, 59.73; H, 3.90; N, 7.74.
3-[1-(4-Chlorophenyl)-3-ethyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl]benzoic acid ethyl ester
(20d) Mp5102–1051C; purified by column chromato-
graphy (cyclohexane/ethyl acetate 3:1); yield516%.1H-
NMR (CDCl3), d: 1.35 (3H, t, J57.1 Hz), 1.40 (3H, t,
J57.2 Hz), 4.15 (2H, q, J57.1 Hz), 4.40 (2H, q,
J57.2 Hz), 7.40 (2H, d, J58.4 Hz), 7.50–7.55 (4H, m),
7.65 (1H, d, J58.4 Hz), 7.85 (1H, d, J58.4 Hz), 8.15
(1H, m). Anal. Calcd for C21H19ClN2O4: C, 63.24; H,
4.80; N, 7.02. Found: C, 63.37; H, 4.81; N, 7.03.
3-[1-(4-Chlorophenyl)-3-ethyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl]benzonitrile (20e) Mp5
163–1641C; purified by column chromatography (to-
luene/ethyl acetate 8:2); yield520%. 1H-NMR (CDCl3),
d: 1.35 (3H, t, J57.2 Hz), 4.15 (2H, q, J57.2 Hz), 7.40
(2H,d, J58.5 Hz), 7.45–7.55 (4H, m), 7.65 (1H, d,
J58.5 Hz), 7.80 (1H, d, J58.5 Hz), 8.00 (1H, s). Anal.
Calcd for C19H14ClN3O2: C, 64.87; H, 4.01; N, 11.94.
Found: C, 65.06; H, 4.02; N, 11.98.
1-(4-Chlorophenyl)-5-(3,4-dimethoxyphenyl)-
3-ethyl-1H-pyrimidine-2,4-dione (20f) Mp5
66–681C; purified by column chromatography (to-
luene/ethyl acetate 8:2); yield5 19%. 1H-NMR
(CDCl3), d: 1.35 (3H, t, J5 7.2 Hz), 3.90 (3H, s), 3.95
(3H, s), 4.15 (2H, q, J5 7.2 Hz), 6.90 (1H, m), 7.05
(1H, d, J5 7.9 Hz), 7.20 (1H, s), 7.40–7.50 (5H, m).
Anal. Calcd for C20H19ClN2O4: C, 62.10; H, 4.95; N,
7.24. Found: C, 62.29; H, 4.96; N, 7.26.
3-Ethyl-5-(3-nitrophenyl)-1-p-tolyl-1H-pyrimi-
dine-2,4-dione (20g) Mp5 162–1641C; purified by
column chromatography (toluene/ethyl acetate 8:2);
yield5 34%. 1H-NMR (CDCl3), d: 1.35 (3H, t,
J5 7.2 Hz), 2.45 (3H, s), 4.20 (2H, q, J5 7.2 Hz),
7.25–7.40 (4H, m), 7.60 (2H, m), 8.00 (1H, d,
J5 8.9 Hz), 8.20 (1H, d, J5 8.9 Hz), 8.40 (1H, s). Anal.
Calcd for C19H17N3O4: C, 64.95; H, 4.88; N, 11.96.
Found: C, 65.14; H, 4.89; N, 12.00.
5-(3-Chlorophenyl)-3-ethyl-1-p-tolyl-1H-pyri-
midine-2,4-dione (20h) Mp5 40–421C; purified by
281NITRAQUAZONE PDE4 INHIBITORS
Drug Dev. Res.
column chromatography (cyclohexane/ethyl acetate
3:1); yield5 31%. 1H-NMR (CDCl3), d: 1.35 (3H, t,
J5 7.2 Hz), 2.45 (3H, s), 4.15 (2H, q, J5 7.2 Hz),
7.30–7.60 (9H, m). Anal. Calcd for C19H17ClN2O2: C,
66.96; H, 5.03; N, 8.22. Found: C, 67.16; H, 5.05; N,
8.24.
3-(3-Ethyl-2,4-dioxo-1-p-tolyl-1,2,3,4-tetrahy-
dropyrimidin-5-yl)benzoic acid ethyl ester (20i)
Mp5 97–1001C; purified by column chromatography
(cyclohexane/ethyl acetate 3:1); yield5 15%.
1H-NMR (CDCl3), d: 1.35 (3H, t, J5 7.2 Hz),
1.40 (3H, t, J5 7.3 Hz), 2.45 (3H, s), 4.20 (2H, q,
J5 7.2 Hz), 4.40 (2H, q, J5 7.3 Hz), 7.20–7.70 (6H,
m), 7.90 (1H, d, J5 8.2 Hz), 8.05 (1H, d, J5 8.2 Hz),
8.15 (1H, s). Anal. Calcd for C22H22N2O4: C, 69.83; H,
5.86; N, 7.40. Found: C, 69.69; H, 5.85; N, 7.39.
3-Ethyl-5-(3-nitrophenyl)-1-phenyl-1H-pyri-
midine-2,4-dione (20j) Mp5 151–1541C; crystal-
lization solvent5EtOH; yield5 26%. 1H-NMR
(CDCl3), d: 1.30 (3H, t, J5 7.2 Hz), 4.15 (2H, q,
J5 7.2 Hz), 7.35–7.55 (5H, m), 7.65–7.75 (2H, m),
8.00 (1H, d, J5 8.5 Hz), 8.30 (1H, d, J5 8.5 Hz), 8.55
(1H, s). Anal. Calcd for C18H15N3O4: C, 64.09; H,
4.48; N, 12.46. Found: C, 63.96; H, 4.47; N, 12.44.
5-(3-Chlorophenyl)-3-ethyl-1-phenyl-1H-pyr-
imidine-2,4-dione (20k) Mp5 42–441C; purified by
column chromatography (cyclohexane/ethyl acetate
2:1); yield5 19%. 1H-NMR (CDCl3), d, ppm: 1.35
(3H, t, J5 7.2 Hz), 4.20 (2H, q, J5 7.2 Hz), 7.30–7.60
(10H, m). Anal. Calcd for C18H15ClN2O2: C, 66.16; H,
4.63; N, 8.57. Found: C, 66.29; H, 4.64; N, 8.59.
3-(3-Ethyl-2,4-dioxo-1-phenyl-1,2,3,4-tetra-
hydropyrimidin-5-yl)benzoic acid ethyl ester
(20l) Mp5 50–521C; purified by column chromato-
graphy (cyclohexane/ethyl acetate 3:1); yield5 17%.
1H-NMR (CDCl3), d: 1.35 (3H, t, J5 7.2 Hz),
1.40 (3H, t, J5 7.0 Hz), 4.20 (2H, q, J5 7.2 Hz), 4.40
(2H, q, J5 7.0 Hz), 7.40–7.60 (7H, m), 7.85 (1H, d,
J5 8.3 Hz), 8.05 (1H, d, J5 8.3 Hz), 8.15 (1H, s). Anal.
Calcd for C21H20N2O4: C, 69.22; H, 5.53; N, 7.69.
Found: C, 69.36; H, 5.54; N, 7.71.
5-(3-Chlorophenyl)-3-cyclopropylmethyl-1-
phenyl-1H-pyrimidine-2,4-dione (20m) Mp5
47–481C; purified by column chromatography (cy-
clohexane/ethyl acetate 3:1); yield5 23%. 1H-NMR
(CDCl3), d: 0.4–0.5 (4H, m), 1.35 (1H, m), 4.00 (2H,
d, J5 6.9 Hz), 7.30–7.55 (10H, m). Anal. Calcd for
C20H17ClN2O2: C, 68.09; H, 4.86; N, 7.94. Found: C,
67.95; H, 4.85; N, 7.92.
5-(4-Chlorobenzylamino)-1-(4-chlorophenyl)-
1H-pyrimidine-2,4-dione (21) A mixture of 5-bromo
derivative 10a (0.5 mmol) and 4-chlorobenzylamine
(4.0 mmol) was heated in a sealed tube at 901C for
9 h. After cooling, the residue was treated with EtOH
(2 mL) and cold water was added (25 mL) and the
mixture was extracted with ethyl acetate (3 20).
Evaporation of the solvent afforded a residue that
was crystallized by EtOH. Mp5 243–2461C; crystal-
lization solvent5EtOH; yield5 17%.1H-NMR
(CDCl3), d: 4.10 (2H, d), 5.30 (1H, exch br t), 6.45
(1H, s), 7.30–7.40 (6H, m), 7.50 (2H, d, J5 8.6 Hz).
5-(4-Chlorobenzylamino)-1-(4-chlorophenyl)-
3-ethyl-1H-pyrimidine-2,4-dione (22) Mp5 186–1871C;
crystallization solvent5EtOH; yield5 60%. 1H-NMR
(DMSO), d: 1.10 (3H, t, J5 7.2 Hz), 3.90 (2H, q, J5
7.2 Hz), 4.10 (2H, d), 5.35 (1H, exch t), 6.50 (1H, s),
7.35 (6H, m), 7.50 (2H, d, J5 8.6 Hz).
Anal. Calcd for C19H17Cl2N3O2: C, 58.47; H,
4.39; N, 10.77. Found: C, 58.65; H, 4.40; N, 10.80.
General Procedure for Compounds (24a–c)
Compounds 24a–c were obtained starting from
23a,b following the general procedure described for
12a,b. For compounds 24a,c, the reaction was carried
out in anhydrous DMF, the suspension was diluted
with cold water and the precipitate 24a was recovered
by suction and recrystallized by ethanol. Compound
24c was obtained by extraction with CH2Cl2
(3 15 mL) and was purified by column chromatography
using toluene/ethyl acetate 8:2, as eluent. For compound
24b, the reaction was carried out in anhydrous CH3CN
and suspension was diluted with cold water and extracted
with CH2Cl2 (3 15 mL) to afford a residue that was
purified by column chromatography using cyclohexane/
ethyl acetate 2:1, as eluent.
5-(3,4-Dimethoxyphenyl)-1-ethyl-2-oxo-1,2-
dihydropyridine-3-carbonitrile (24a) Mp5 112–1141C;
crystallization solvent5EtOH; yield5 60%. 1H-NMR
(CDCl3), d: 1.50 (3H, t, J5 7.2 Hz), 2.50 (3H, s), 3.90
(3H, s), 3.95 (3H, s), 4.55 (2H, q, J5 7.2 Hz), 6.75 (1H,
s), 6.85–6.95 (2H, m), 7.70 (1H, s). Anal. Calcd for
C17H18N2O3: C, 68.44; H, 6.08; N, 9.39. Found: C,
68.65; H, 6.10; N, 9.42.
1-Cyclopropylmethyl-2-oxo-5-phenyl-1,2-dihy-
dropyridine-3-carbonitrile (24b) Mp5117–1181C;
purified by column chromatography (cyclohexane/ethyl
acetate 2:1); yield5 30%. 1H-NMR (CDCl3), d: 0.60
(4H, m), 1.15 (1H, m), 2.45 (3H, s), 4.15 (2H, d,
J56.9 Hz), 7.20 (2H, m), 7.40 (3H, m), 7.70 (1H, s).
Anal. Calcd for C17H16N2O: C, 77.25; H, 6.10; N,
10.60. Found: C, 77.10; H, 6.09; N, 10.59.
1-Cyclopropylmethyl-5-(3,4-dimethoxyphenyl)-
2-oxo-1,2-dihydropyridine-3-carbonitrile (24c) Mp5
107–1091C; purified by column chromatography (to-
luene/ethyl acetate 8:2); yield530%.
1H-NMR (CDCl3), d: 0.45 (2H, m), 0.65 (2H, m),
1.40 (1H, m), 2.45 (3H, s), 3.90 (3H, s), 3.95 (3H, s),
4.30 (2H, d, J56.8 Hz), 6.75 (1H, s), 6.85–6.95 (2H, m),
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7.70 (1H, s). Anal. Calcd for C19H20N2O3: C, 70.35; H,
6.21; N, 8.64. Found: C, 70.49; H, 6.22; N, 8.66.
Pharmacology
PDE4 activity assay
Experiments were conducted using undifferen-
tiated U937 cells. As previously demonstrated [Mackenzie
and Houslay, 2000], this human monocytic cell line
express a range of cAMP-specific phosphodiesterase
(PDE) isoenzymes: PDE4A, PDE4B, and PDE4D,
which provide around 76% of the total cAMP PDE
activity of U937 cells. Only approximately 9% of the
cAMP PDE activity in U937 cells was due to PDE3.
Cell culture
U937 cells were grown in plastic dishes in RPMI-
1640 medium supplemented with 10% FCS,
L-glutamine 2 mM and 50 U/mL of penicillin G and
0.05 mg/mL streptomycin at 371C in a humidified
atmosphere of 95% air-5% CO2 and culture medium
changed every two days. Cells were harvested at a
density of approximately 1.0 106 cells per mL; in all
experiments, the medium was removed by centrifuga-
tion at 300 g for 5 min at room temperature and cells
washed in PBS buffer (pH5 7.4) and re-centrifuged.
The cells were resuspended in 50 mM ice-cold TRIS-
HCl buffer (pH5 7.4) containing 1 mM PMSF and
sonicated on ice four times for 25 sec. The sonically
disrupted cells were centrifuged at 12,000g for 10 min;
aliquots of the supernatant fraction were assayed for
PDE activity using a modification of the method of
Morelli et al. [2004] as described below. Protein
concentration was determined using the Bradford
method [Bradford, 1976].
cAMP assay
Aliquots of supernatant fraction of fresh cell
lysates (50mL) were incubated in a final volume of
200 mL for 20 min at 301C with 50 nM [3H]-cAMP,
1 mM cold cAMP in TRIS-HCl buffer containing 1 mM
PMSF with or without PDE4 inhibitors. To inhibit the
activity of the small fraction of PDE3, all samples were
added with 1 mM cilostamide. The total PDE activity of
the cell preparation was measured in the absence of
inhibitors and total PDE4 activity was measured
adding the selective inhibitor, rolipram (10 mM). All
compounds were evaluated at a single final concentra-
tion of 10mM. Compounds that exhibited activity in
single-dose testing were further evaluated to generate
dose response curves, which were used to determine
IC50 values. Reactions were terminated by boiling for
1 min, each sample was then supplemented with a
mixture of carriers (60 mL of a solution containing
3 mM cAMP, AMP, and adenine), and placed on ice for
10 min. In order to separate and quantify the amounts
of nucleotides and adenine, aliquots of 40mL of each
sample were deposed on 60 F254 silica gel plates
(eluent ethanol:H2O, 70:30 v/v). Under UV light, three
different lanes were identified, corresponding to cAMP,
AMP, and adenine, which have the same ratio frontis of
the standard molecules comigrated on the same plate.
Then the three different lanes were separated by
scraping, the silica powder collected and placed into
plastic vials; the radioactivity was extracted with 1 mL
water, added with 6 mL of InstagelPlus scintillation
liquid (Perkin-Elmer Life and Analytical Science,
Boston, MA) and counted in a TRICARB 1900TR
Scintillation Counter (Perkin-Elmer Life and Analyti-
cal Science, Boston, MA).
Enzymatic activity was measured as percentage of
substrate into product conversion as follows: conver-
sion (%)5 [products count/(substrate1products
counts)] 100. At the same time, 40mL of the sample
were placed into vials with scintillation cocktail and
counted for radioactivity in order to obtain the recovery
of each sample: in these experimental conditions, the
total recovery was about 90%.
[3H] Rolipram Binding
Membrane preparation
Male Sprague-Dawley rats (Harlan, Italy) were
housed in a temperature- and light-controlled room
and were allowed free access to food and water. Their
experimental use was conducted in accordance with
the European Communities Council Directive of 24
November 1986 (86/609/EEC) for experimental animal
care.
Rats were killed by decapitation and the cerebral
cortex was dissected on ice and homogenized in buffer
(50 mM Tris-HCl, 5 mM MgCl2, pH 7.5) using an
Utraturrax homogenizer at 16,000 rpm. Separation of
supernatant and particulate fractions was achieved by
centrifugation at 15,000g for 15 min at 41C and the
pellet was then resuspended in the same buffer.
Binding studies
[3H]Rolipram binding was measured following a
modification of the method of Schneider et al. [1986].
For heterologous competition assays, 2 nM [3H]Roli-
pram was incubated with membrane preparations
containing 0.2–0.3 mg of protein at 301C in a final
volume of 0.25 mL in the presence of increasing
concentrations of the newly synthesized compounds.
For mixed homologous saturation binding assays,
[3H]Rolipram was present at 0.2 nM in tubes contain-
ing increasing concentrations of unlabeled Rolipram
(0.03–1000 nM) and at 0.075–0.2 nM in tubes without
unlabeled ligand. Reactions were stopped after 1 h by
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addition of 5 mL of ice-cold buffer and rapid vacuum
filtration through glass fiber filters (Whatman GF/C,
Florham Park, NJ) presoaked in a 0.3% polyethyleni-
mine (PEI) solution. The filters were washed twice
with 5 mL of ice-cold buffer, 6 mL of scintillation liquid
(FilterCount, Perkin-Elmer Life and Analytical
Science, Boston, MA) was added and radioactivity
measured in a scintillation beta counter. Binding data
were evaluated quantitatively with the weighted least-
squares iterative curve fitting LIGAND program
[Munson and Rodbard, 1980], to obtain the Ki values.
PDE3 and PDE5 activity assay
Platelets contain three classes of PDEs: PDE2,
PDE3, and PDE5 [Roma et al., 2007]. PDE2
hydrolyzes both cAMP and cGMP. The PDE3 isoform
is the most abundant and preferentially hydrolyzes
cAMP, while PDE5 is a specific inactivator of cGMP.
Preparation of disrupted platelet suspension
Human blood was freshly drawn from healthy
volunteers, who gave informed consent and had not
taken medication for at least 2 weeks. Blood was
collected into ACD (2.5% sodium citrate, 1.5% citric
acid, and 2% glucose) solution (6:1 [v/v]) and
centrifuged at 200g for 20 min to generate platelet-
rich plasma (PRP). The latter was then centrifuged at
1,000g for 10 min, resuspended in Tyrode’s buffer
(138 mmol/L NaCl, 2.7 mmol/L KCl, 2 mmol/L MgCl2,
0.42 mmol/L NaH2PO4, 5 mmol/L glucose, 10 mmol/L
HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfo-
nic acid], and 0.2% bovine serum albumin, pH 7.4)
and re-centrifuged. Platelets were resuspended in
50 mM ice-cold TRIS-HCl buffer (pH5 7.4) containing
1 mM PMSF and sonicated on ice four times for 30 sec.
The disrupted platelet suspension was centrifuged at
12,000g for 20 min. The soluble fraction contains about
70–80% of the cAMP PDE activity, as described [Grant
and Colman, 1984]. This fraction was assayed both for
cAMP and cGMP PDE activity.
cAMP and cGMP assay
PDE activity was measured in TRIS-HCl buffer
containing 1 mM PMSF. Aliquots of fresh platelet
lysate suspension (50mL) were incubated in a final
volume of 200mL for 15 min at 301C with substrates
([3H]-cAMP or [3H]-cGMP 50 nM, and cold cAMP or
cold cGMP 1mM), with or without inhibitors. All
experiments were performed in the presence of 10mM
erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) to
selectively inhibit PDE2 activity. Total PDE3 activity
was determined in the presence of 10 mM cilostamide
and total PDE5 activity was measured in the presence
of 10mM sildenafil. cAMP and cGMP assays were
performed as described above. For PDE5 activity, the
mixture of carriers used was composed by a solution
containing 3 mM cGMP, GMP, and guanine.
RESULTS AND DISCUSSION
Experiments to measure the inhibitory activity on
PDE4 isoenzyme of the new synthesized compounds
were assessed in fresh cell lysates of human U937
monocytic cells. The PDE4 selective inhibitor, roli-
pram (10mM), and the PDE3 selective inhibitor,
cilostamide (1mM), were used to determine the activity
of these enzyme families in U937 cell lysates. This
method allowed us to determine that the majority of
the cAMP PDE activity in U937 monocytic cells was
due to the actions of these two PDE families. PDE
activity in U937 cell lysate attributable to PDE4 was
defined experimentally as that inhibited by 10mM
rolipram. PDE4 was found to be the predominant
isoform (80% of the total cAMP PDE activity) as
previously reported [Torphy et al., 1992]. Moreover, to
evaluate the isoenzyme selectivity of the newly
synthesized PDE4 inhibitors, their effects on PDE3
and PDE5 activities were examined. For PDE5,
sildenafil was used as a reference drug. The source of
these two PDE isoforms was human platelets, and in
order to characterize the differences between the PDE
isoforms present in platelets, the inhibitory effects of
various PDE inhibitors were evaluated. The reference
PDE2-selective inhibitor, EHNA, was used in all
experiments in order to exclude the activity of this
isoform.
Biological data on the newly synthesized com-
pounds are shown in Tables 1 and 2. For most
compounds, we inserted an ethyl group at position 3
of the pyrimidindione nucleus according to the
requirement for nitraquazone analogs. Starting the
analysis from 5-anilino substituted pyrimidindiones
(compounds 13–18, Table 1) we observed that
compounds 13a,b and 18a–c, in which the phenyl
ring at position 1 was substituted in para with a
chlorine (13a,b), a nitro group (18a,b), or an amino
group (18c), demonstrated appreciable activity as
PDE4 inhibitors with IC50 values in the micromolar
range. In particular, compound 13a, bearing a nitro
group in the meta position of the aniline moiety, had an
IC505 6.54mM, being 2-fold more potent than the
corresponding para chlorine derivative 13b. In deri-
vatives 18a,b, the anilino compound substituted with
an ethoxy carbonyl group (18b) was approximately
3-fold more potent with respect to the corresponding
3-Cl anilino derivative 18a (IC50 values of 5.72 and
17.54mM, respectively). Compound 18c was also active
in the micromolar range. When the phenyl ring at
position 1 was substituted with a methyl group, no
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PDE4 inhibitory activity was observed (compounds
13c,d). All active compounds exhibited good selectivity
toward PDE3, and PDE5 isoenzymes and demon-
strated a low affinity for HARBS with IC50 values
between 12 and 69mM (IC50 for Rolipram5 3.6 nM).
The observed selectivity versus HARBS (HARBS/
PDE4) is appreciable for compound 13a (10) and
decreased for other compounds (HARBS/
PDE45 0.9–4.5). The introduction of a methylenic
spacer between the amino group at position 5 of the
pyrimidindione system and the phenyl ring in com-
pound 13b was detrimental for the activity (compound
22) (PDE4 inhibition5 23% at 10mM). Analysing the
5-phenyl pyrimidindiones (20a–m), it is clear that a
methyl or a chlorine substitution at the phenyl ring
linked at position 1 of the pyrimidindione nucleus led
to inactive compounds independent of the nature of
substituent X present in the phenyl at position 5
(compounds 20a–i). When R5H and R15 ethyl
(compounds 20j–l), moderate activity was dependent
on the substituent X, since 20j (X5 3-NO2) is inactive,
while 20k and 20l (3-Cl and 3-COOEt, respectively)
had IC50 values of approximately 40mM. Replacement
of the ethyl at position 3 in compound 20k with
cyclopropylmethyl (compound 20m) increased PDE4
inhibitory activity by an order of magnitude
TABLE 1. Inhibitory Effect of Newly Synthesized Compounds on PDE4, PDE3, PDE5 Activities and Displacement of [3H] Rolipram From Its
Binding Sites (HARBS)
N
N
O
O R
HN
Et
X
N
N
O
O R
R1
X
N
N
O
O Cl
HN
H2C
Cl
Et
m-a0281-31
22 
Compd. R R1 X PDE4
a,b PDE3a,c PDE5a,c [3H] Roliprama
13a Cl – 3-NO2 6.5471.38 N.A. N.A. 67.07714.11
13b Cl – 4-Cl 13.3272.75 N.A. N.A. 12.2571.42
13c Me – 3-NO2 14.1770.32 (10) – –
13d Me – 3-COOEt 11.7071.74 (10) – –
18a NO2 – 3-Cl 17.5472.82 N.A. N.A. 69.53711.20
18b NO2 – 3-COOEt 5.7270.80 5.179.17(10) 1.29711.95 (10) 25.5077.32
18c NH2 – 3-COOEt 10.4672.19 N.A. N.A. 24.1671.99
20a Cl Et H 12.1270.88 (10) – –
20b Cl Et 3-NO2 0.6279.92 (10) – – –
20c Cl Et 3-Cl N.A. – – –
20d Cl Et 3-COOEt 18.5772.50 (10) – – –
20e Cl Et 3-CN 12.9875.63 (10) – – –
20f Cl Et 3,4-OMe 23.4970.72 (10) – – –
20g Me Et 3-NO2 11.2573.09 (10) – – –
20h Me Et 3-Cl 14.34710.84 (10) – – –
20i Me Et 3-COOEt 10.3279.08 (10) – – –
20j H Et 3-NO2 N.A. – – –
20k H Et 3-Cl 42.92710.92 N.A. 2.9473.24 (10) 25.9176.30
20l H Et 3-COOEt 39.1474.49 N.A. N.A. 26.7375.91
20m H 3-Cl 4.8771.37 N.A. N.A. 12.5571.16
22 – – – 22.7773.36 (10) – – –
Rolipram 0.3170.06 N.A. 0.6170.60 (10) 0.003670.0001
Cilostamide – 70.3276.61(10) N.A. –
Sildenafil N.A. N.A. 79.3975.94 (10) –
aData are expressed as IC50 (mM)7SEM or inhibition percentage at indicated concentration (mM).
bIn the presence of cilostamide 1 mM.
cIn the presence of EHNA 10mM. N.A.5 not active.
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(IC5054.87mM). Analogous to the 5-anilino series
(compounds 13–18), these compounds showed high
selectivity versus PDE3 and PDE5 isoenzymes, but no
selectivity toward HARBS, the only exception being
compound 20m (HARBS/PDE452.6). In the pyridones
24a–c (Table 2), the ethyl derivative (24a) was inactive
showing 22% inhibition at 10mM. Also as previously
described for compound 20m, substitution of the ethyl
group with cyclopropylmethyl increased activity. Com-
pound 24c had an IC50 of 15.5mM, was selective versus
PDE3, PDE5, and in particular versus HARBS, showing
an IC504500mM. Compound 24b with a cyclopropyl-
methyl group at position 1 and an unsubstituted phenyl
at position 6 had similar PDE4 inhibitory potency and
PDE3 and PDE5 selectivity, but a reduced selectivity
versus HARBS (HARBS/PDE45 2.4).
In conclusion, we synthesized new PDE4 in-
hibitors with pyrimidindione or pyridinone scaffold as
simplified analogs of nitraquazone. Preliminary results
demonstrated that the 5-anilino derivatives (com-
pounds 13–18) showed the best biological profile
combining a moderate PDE4 inhibitory activity with a
good selectivity toward PDE3 and PDE5. Replacement
of the ethyl at position 3 with a cyclopropylmethyl
group in the 5-phenyl series and its introduction
at position 1 in the pyridone series led to an increase
in PDE4 inhibitory activity (compounds 20m and
24c). These data suggest that this fragment could be
the optimal group for this position. Further studies
are ongoing to optimise the profile of this compound
series.
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